TFPI-2 Overview
Molecule Name
DNA-(apurinic or apyrimidinic site) lyase
Synonyms
TFPI2,PP5,REF1
Drug Development Progress
Drugs in Clinical Trials1
Approved Drugs0
Highest Development StagePhase 2 Clinical
Target Synonym
AP endonuclease 1，DNA-(apurinic or apyrimidinic site) lyase，APE1，APEN，REF-1，Apurinic-apyrimidinic endonuclease 1，APEX nuclease，REF1，APEX，APEX1，Apurinic/Apyrimidinic Endodeoxyribonuclease 1，APEX Nuclease (Multifunctional DNA Repair Enzyme) 1，Redox Factor-1，HAP1，APE，APX，APEX Nuclease (Multifunctional DNA Repair Enzyme)，Deoxyribonuclease (Apurinic Or Apyrimidinic)，Apurinic/Apyrimidinic (Abasic) Endonuclease，AP Endonuclease Class I，Protein REF-1，AP Lyase，APE-1，DNA-(apurinic or apyrimidinic site) endonuclease
Background
Tissue Factor Pathway Inhibitor 2 (TFPI2) is also known as placental protein 5 (PP5) and retinal pigment epithelial cell factor 1 (REF1), is a member of the Kunitz-type serine proteinase inhibitor family, is a structural homologue of tissue factor pathway inhibitor (TFPI). TFPI2 is highly abundant in the full-term placenta and widely expressed in umbilical vein endothelial cells, liver, placenta, heart, pancreas, and maternal serum at advanced pregnancy. TFPI2 may play a role in the regulation of plasmin-mediated matrix remodeling. Inhibits trypsin, plasmin, factor VIIa/tissue factor and weakly factor Xa and has no effect on thrombin. Reduced synthesis of TFPI-2 has been related to numerous pathophysiological processes such as inflammation, angiogenesis, atherosclerosis, retinal degeneration and tumor growth / metastasis.
TFPI-2 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| APX-3330 | APX-3330; APX3330; E-3330 | Phase 2 Clinical | Eisai Co Ltd | Solid tumours; Inflammatory Bowel Diseases; Neoplasms; Diabetic macular oedema; Diabetic Retinopathy | Details |